Search ARN News Centre
Business from Friday, December 20th, 2024
-
Novo's next-gen obesity drug candidate trial disappoints
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
